Theratechnologies Inc. – Company Overview
Theratechnologies Inc. is a biopharmaceutical company headquartered in Montreal, Canada. The company focuses on the development and commercialization of various therapies to address unmet medical needs in the healthcare sector, specifically in biotechnology. Theratechnologies primarily operates in the United States, Canada, and Europe.
The company's flagship product is EGRIFTA SV, which is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies also offers Trogarzo, a treatment for HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
In addition to its existing products, Theratechnologies has a pipeline of promising candidates in various stages of development. This includes the F8 Formulation, which is currently undergoing Phase 2b/3 clinical trials for the treatment of nonalcoholic steatohepatitis. The company is also developing a multi-dose pen injector for the administration of tesamorelin and a SORT1+ Technology Platform for cancer drug development.
Theratechnologies has a team of experienced executives leading the company, including Mr. Paul Lévesque as the President, CEO, and Director. Other key executives include Mr. Philippe Dubuc as the Senior VP and CFO, Mr. Jocelyn Lafond as the General Counsel and Corporate Secretary, Dr. Christian Marsolais as the Senior VP and Chief Medical Officer, Mr. John Leasure as the Global Commercial Officer, and Hon. Andre Dupras as the Vice President of Human Resources.
The company's financials indicate a market capitalization of $67.27 million, with a trailing EPS of -$0.91. Theratechnologies has a beta of 1.73, indicating a higher risk profile compared to the market. The stock has a 52-week range of $0.88 to $4.32.
Theratechnologies does not currently offer dividends, and the forward dividend yield is not available.
Analysts have provided a 1-year target estimate for Theratechnologies stock at $8.67.
Financial Summary
- Previous Close: $1.39
- Open: $1.46
- Bid: $1.09 x 200
- Ask: $1.85 x 200
- Day's Range: $1.41 – $1.53
- 52 Week Range: $0.88 – $4.32
- Volume: 55,927
- Average Volume: 76,224
- Market Cap: $67.27 million
- Beta (5Y Monthly): 1.73
- PE Ratio (TTM): N/A
- EPS (TTM): -$0.91
- Earnings Date: Apr 10, 2024 – Apr 15, 2024
- Forward Dividend & Yield: N/A (N/A)
- Ex-Dividend Date: N/A
- 1-Year Target Estimate: $8.67
Historical Stock Price Data
The historical stock price data for Theratechnologies Inc. over the past 125 trading days is as follows:
- Start Date: January 27, 2023
- End Date: August 4, 2023
The stock price has ranged from a low of $0.88 to a high of $4.32 during this period. The average daily volume is 76,224 shares.
Conclusion
Theratechnologies Inc. is a biopharmaceutical company focused on developing and commercializing therapies in the healthcare sector. The company's products and pipeline candidates target unmet medical needs, particularly in the treatment of HIV and nonalcoholic steatohepatitis.
While the company's financials indicate a negative trailing EPS and a higher risk profile, analysts have provided a 1-year target estimate of $8.67 for Theratechnologies stock.
Investors should carefully consider the company's financial performance, pipeline progress, and market conditions before making investment decisions.
